Allergen immunotherapy (AIT) is the only disease‐modifying treatment of type I allergy. We investigated adult patients with grass pollen–induced allergic rhinoconjunctivitis ± allergic asthma and low serum 25(OH)D. The distinct difference in the vitamin D status provides the molecular basis to determine the impact of vitamin D on AIT, which we assessed by clinical and immunologic parameters.